These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28261269)

  • 1. Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats.
    Khoza S; Moyo I; Ncube D
    J Toxicol; 2017; 2017():6746989. PubMed ID: 28261269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK; Gregurek-Novak T
    Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
    Gupta AK
    Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial.
    Singh S; Chandra U; Anchan VN; Verma P; Tilak R
    Br J Dermatol; 2020 Nov; 183(5):840-846. PubMed ID: 32538466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole.
    Gupta AK; Adam P; Dlova N; Lynde CW; Hofstader S; Morar N; Aboobaker J; Summerbell RC
    Pediatr Dermatol; 2001; 18(5):433-8. PubMed ID: 11737692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.
    Back DJ; Tjia JF
    Br J Clin Pharmacol; 1991 Nov; 32(5):624-6. PubMed ID: 1659439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral therapeutic agents in fungal nail disease.
    Roberts DT
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S78-81. PubMed ID: 8077514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole.
    Wingfield AB; Fernandez-Obregon AC; Wignall FS; Greer DL
    Br J Dermatol; 2004 Jan; 150(1):119-26. PubMed ID: 14746625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.
    García Rodríguez LA; Duque A; Castellsague J; Pérez-Gutthann S; Stricker BH
    Br J Clin Pharmacol; 1999 Dec; 48(6):847-52. PubMed ID: 10594489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic optimisation of oral antifungal therapy.
    Schäfer-Korting M
    Clin Pharmacokinet; 1993 Oct; 25(4):329-41. PubMed ID: 8261715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
    Bergman W; Rutten FF
    Ned Tijdschr Geneeskd; 1994 Nov; 138(47):2346-50. PubMed ID: 7969635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
    Marchetti A; Piech CT; McGhan WF; Neugut AI; Smith BT
    Clin Ther; 1996; 18(4):757-77; discussion 702. PubMed ID: 8879902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azoles, allylamines and drug metabolism.
    Back DJ; Tjia JF; Abel SM
    Br J Dermatol; 1992 Feb; 126 Suppl 39():14-8. PubMed ID: 1311943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A questionnaire study on the management of onychomycosis: a Canadian perspective.
    Gupta AK; Shear NH
    Int J Dermatol; 1998 Jun; 37(6):457-60. PubMed ID: 9646138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current trends in onychomycosis therapy: a literature review.
    Hecker D
    Mt Sinai J Med; 1997 Nov; 64(6):399-405. PubMed ID: 9364835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of oral antifungal agent-induced liver injury in Taiwanese.
    Kao WY; Su CW; Huang YS; Chou YC; Chen YC; Chung WH; Hou MC; Lin HC; Lee FY; Wu JC
    Br J Clin Pharmacol; 2014 Jan; 77(1):180-9. PubMed ID: 23750489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatments for tinea capitis.
    Chan YC; Friedlander SF
    Curr Opin Infect Dis; 2004 Apr; 17(2):97-103. PubMed ID: 15021047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of oral antifungal agents to treat onychomycosis.
    Gupta AK; Ryder JE
    Dermatol Clin; 2003 Jul; 21(3):469-79, vi. PubMed ID: 12956199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.